NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

Promethera added that it and EMD Millipore, a division of Germany's Merck KGaA, are receiving €900,000 ($1.2 million) from the Belgian Walloon Region Biocluster and the Massachusetts Life Sciences Center to support development of the assay, which is being designed so that "more robust studies in pre-clinical toxicity and drug metabolism" can be achieved.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.